Compare moats
Up to three covered companies, band by band. Every call is a curated editorial judgment, never a disclosed figure — and every band carries its cited basis.
| IREN | Pfizer | Space Exploration Technologies Corp. (SpaceX) | |
|---|---|---|---|
| Moat rating | none The FY2026 10-K (filed 2026-08-27) shows IREN holds an input the industry competes on: it names 'access to secured and energized power' first among what it believes are the principal competitive factors in its industry, and reports 'executed grid connection agreements, letters of agreement or equivalents representing approximately 5GW of total power capacity' in the United States, Canada, Spain and Australia as of June 30, 2026. It does not claim an advantage over rivals in that input. It says 'Certain competitors may have access to more competitively priced power, a greater access to power and a better capacity to timely secure grid connections,' and 'Many of our competitors have greater financial, technical or commercial resources, longer cloud operating histories or larger customer bases, compared to us.' Operating AI Cloud Services capacity was approximately 40MW at June 30, 2026, and the stored XBRL fundamentals from this 10-K show an FY2026 operating loss of about $1,046.7M on revenue of about $707.0M, so no durable advantage is yet demonstrated. | eroding The FY2025 10-K publishes the expiry schedule of its own protection. The Patents table dates the basic U.S. product patent on Eliquis ($7,961 million of 2025 revenue) to 2027, the Prevnar family's Prevnar 13 ($6,494 million for the family) to 2026, the Vyndaqel family ($6,380 million) to 2026 with a 2028 extension only pending, Ibrance ($4,122 million) to 2027, Xtandi ($2,194 million) to 2027 and Xeljanz ($1,087 million) to 2026 - against Total revenues of $62,579 million. The filing then states it anticipates 'a significant reduction of revenue from patent-based or regulatory exclusivity expiries in 2026 through 2030 as several of our in-line products experience these expirations, with the rate of the reduction of revenues from patent-based or regulatory exclusivity expiries expected to significantly accelerate over the next few years', and puts the 2026 instalment at $1.5 billion. A protection whose end dates the issuer tabulates product by product, and whose revenue effect it forecasts as accelerating, is being consumed on a clock it has already disclosed. | narrow The moat is narrow rather than wide. The filing names real entry barriers in launch — capital, technological expertise, licences and established government and commercial relationships — and adds spectrum and orbital resources in connectivity, while warning that the company's "leadership position in various markets, especially in orbital launch services" could attract competition-law scrutiny. The AI segment has barriers too: "Our AI businesses likewise compete in markets characterized by significant barriers to entry." Durability is capped by three-to-five-year satellite lives that force perpetual replacement launches, but the moat is not eroding: subscribers are 12.0M against 6.0M. |
| Moat type | none The FY2026 10-K's asserted advantage is control from owning its data centers, 'including the associated land, grid connections and substations', which it believes allows it 'to benefit from more sustainable cash flows and operational flexibility relative to operators that rely upon third-party colocation services or short-term land leases'. Its only scale language is a belief that its 'procurement scale, deployment experience and direct control over the data center layer' lets it bring new compute into service 'rapidly and at scale', a deployment-speed claim, and it 'generally target[s]' regions with 'low-cost and attractive renewable energy sources', a siting target rather than a demonstrated cost position. It does not claim a cost or scale lead: it says 'Many of our competitors are larger, have longer operating histories and significantly greater resources than we do' and that certain competitors 'may have access to more competitively priced power, a greater access to power and a better capacity to timely secure grid connections.' There is no network effect or lock-in either, since existing contracts have 'terms ranging from month to month up to five years'. No enumerated moat source is grounded. | intangibles ip The filing locates the protection in the patent estate, not anywhere else. The Patents and Other Intellectual Property Rights section tabulates 'the patent rights we consider most significant in relation to our business as a whole, together with the year in which the basic product patent expires', and states that once protection is lost 'we typically lose market exclusivity on these products, and generic and biosimilar pharmaceutical manufacturers generally produce identical or highly similar products and sell them for a lower price.' The Competition section names patents as the thing rivals attack: 'several of our competitors operate without large R&D expenses and make a regular practice of challenging our product patents before their expiration', and 'Generic pharmaceutical manufacturers pose one of the biggest competitive challenges to our branded small molecule products because they can market a competing version of our product after the expiration or loss of our patent protection.' No network, switching cost or cost-curve advantage is claimed anywhere in the section. | cost scale The advantage is cost and scale. The stated model is extreme vertical integration plus reusability driving unit cost down: per NASA, the first Falcon 9 cut launch cost to about $2,700/kg, roughly 85% below the $18,500/kg historical average, and Falcon 9 has "demonstrated the ability to refly a first-stage 34 times" (3/31/26). The filing credits rising cadence, cargo capacity and "declining unit costs—driven by rapid reusability—have generated a compounding competitive advantage". SpaceX also launches its own constellation, and Competition notes "some of these service providers are also launch customers of SpaceX". Spectrum and licence intangibles reinforce the cost advantage. |
| Leadership | behind The 10-K lists IREN's competitors as hyperscalers (Amazon Web Services, Google Cloud, Microsoft Azure, Oracle Cloud) and specialized AI Cloud Services providers (CoreWeave, Nebius, Crusoe, Lambda, Nscale, SpaceX and others). It says IREN began providing AI Cloud Services in 2024 and cites its 'shorter operating history in AI Cloud Services relative to some competitors', and states 'Some of our competitors have longer operating histories, larger customer bases, more comprehensive IP portfolios and patent protections, more design wins, and greater financial, sales, marketing and distribution resources than we do.' Operating AI Cloud Services capacity was approximately 40MW at June 30, 2026. The filing describes a smaller, later entrant that trails some competitors on operating history, customer base and resources, with its progress so far resting on two anchor contracts (a ~$9.7B five-year Microsoft agreement and a ~$3.4B five-year NVIDIA contract) rather than any claimed category position. | co leader The 2026 Pharma 50 (Drug Discovery & Development, published 31 March 2026, ranking pharmaceutical revenue only) places Pfizer third at $62.58 billion of FY2025 revenue inside a five-company band that runs from Johnson & Johnson's Innovative Medicine at $60.40 billion to Eli Lilly's $65.18 billion, with Merck & Co. at $65.01 billion and AbbVie at $61.16 billion in between - scale-equal to its nearest peers rather than ahead of them. The same piece attributes the top slot to Lilly's tirzepatide franchise, which it puts at $36.5 billion combined and says passed Keytruda as the world's best-selling drug; Pfizer's 10-K names no comparable single franchise, discloses no market-share position for any product, and concedes in Item 1A that 'some of our competitors may have competitive, technical or other advantages over us' and that it faces 'an increasing number of potential competitors worldwide, including from China, that have expanded R&D capabilities.' | clear leader SpaceX leads clearly in its two established segments but not in its newest. The prospectus calls it "the primary launch provider for the U.S. government" — 11 of 12 NSSL medium and heavy lift missions and all five U.S. crew and cargo ISS missions for NASA in 2025 — and says Starlink is "the sole low-latency network available globally", low-latency self-defined as under 70ms; it flags competition-law scrutiny risk from that leadership. AI is the exception, with OpenAI, Anthropic, Google, Meta and Microsoft named as competitors, some with greater resources, in a segment the filing calls early stage. Cadence slipped: H1 2026 Falcon launches 77 versus 81, mass to orbit 1,041t versus 1,102t. |
| Pricing power | weak The 10-K's risk factors state 'Our competitors' products, services and technologies may be cheaper or provide better functionality or features than ours, which has resulted and may in the future result in lower-than-expected selling prices or demand for our products.' They also say long-term contract pricing 'is generally fixed or agreed at the time of contracting', so if market pricing for comparable capacity rises during a contract's term 'we will not benefit from those increases with respect to capacity already committed under our existing long-term contracts', and that if customers suffer a downturn or discontinue its services it 'may be compelled to offer more flexible terms, lower our prices or risk losing a significant customer.' The stored XBRL fundamentals from this 10-K show FY2026 revenue of about $707.0M against an operating loss of about $1,046.7M, so there is no margin record yet that evidences pricing power. | weak Price is the lever the filing shows moving against it. CMS selected Eliquis - which the 10-K says 'accounted for 13% of Total revenues in 2025' - for the Medicare Drug Price Negotiation Program, and 'its government-set Maximum Fair Price became effective January 1, 2026', with Ibrance and Xtandi following in 2027 and Xeljanz in 2028. In September 2025 Pfizer 'voluntarily agreed' with the U.S. administration to make certain U.S. prices 'more comparable to those in other developed countries' and to sell through the TrumpRx.gov platform 'at significant discounts to current retail prices'. Gross-to-net product revenue deductions rose to $36,374 million in 2025 from $30,048 million in 2023 while Total revenues fell to $62,579 million, and the IRA Medicare Part D Redesign alone 'negatively impacted our 2025 revenues by approximately $1 billion'. Lower U.S. net price is named as a drag on Vyndaqel, Ibrance, Xeljanz, Nurtec ODT and Lorbrena; every 2025 growth line the filing explains is attributed to demand, patient share or launch uptake, none to price. Cost of sales at 25.7% of revenues shows the manufactured margin is intact - what is not intact is the ability to set the price. | moderate Pricing power is moderate — a deliberate give-back from a cost position rather than weakness. Management states its strategy is "rather than prioritizing increases in ARPU" and expects Starlink ARPU to keep declining as it adds lower-priced plans and adjusts monthly service fees; the Q2 10-Q shows ARPU of $66 versus $85 while Connectivity operating income rose 79.4%. Launch sells on fixed-price contracts, one to five years for Launch Services and up to fourteen for Launch and Development. Concentration is material: about one-fifth of 2025 revenue came from U.S. federal agencies, with all launch contracts firm fixed-price and terminable at the government's convenience without advance notice. |
| Summary | Per its FY2026 10-K, IREN is a vertically integrated AI Cloud Services platform that owns the data center, compute and software layers, underpinned by executed grid connection agreements, letters of agreement or equivalents representing ~5GW and a further multi-GW development pipeline. Its commercial record is concentrated: a five-year Microsoft agreement (~$9.7B total contract value, Horizon 1 delivered and accepted in August 2026, Horizons 2-4 targeted for delivery in phases in calendar Q4 2026) and a five-year ~$3.4B NVIDIA cloud contract together make up a substantial majority of contracted revenue. It holds NVIDIA Preferred Partner and Exemplar Cloud status (HGX B300 and GB300 NVL72) and a strategic partnership intended to support the deployment over time of up to 5GW of NVIDIA DSX-aligned infrastructure, which the filing cites among arrangements that are non-binding or subject to conditions, with no assurance as to the extent of deployments. Against that, the filing names hyperscaler and specialized competitors (AWS, Google Cloud, Azure, Oracle, CoreWeave, Nebius, Crusoe, Lambda, Nscale, SpaceX), many of which it says have greater resources, customers that can use or develop their own solutions, and possible delays to Texas energization from changes to ERCOT's Batch Zero procedures, so the power position is not a demonstrated advantage over rivals and its value depends on execution. | Two clocks run in opposite directions inside the same company. The revenue base is near-dated: Eliquis, the Prevnar family, the Vyndaqel family, Ibrance, Xtandi and Xeljanz all carry U.S. basic product patents expiring 2026 or 2027 in the 10-K's own table, and the filing warns the resulting revenue loss will 'significantly accelerate over the next few years'. The replacement book is later-dated - Padcev and Lorbrena to 2033, Nurtec ODT and Litfulo to 2034, Prevnar 20 to 2035, Abrysvo, Cibinqo and Elrexfio to 2036, Comirnaty and Paxlovid to 2041 - but in 2025 it was still much smaller, and the two products with the longest patent runway are the two the filing says are shrinking fastest (Comirnaty down 20% and Paxlovid down 59% operationally). The 10-K's answer is purchased pipeline rather than defended position: it cites the Seagen and Metsera acquisitions as 'significant investments in obesity and oncology, respectively, which are extremely competitive therapeutic areas', while R&D expense itself fell 4% to $10,437 million. Excluding Comirnaty and Paxlovid the remaining business grew 6% operationally in 2025, which is the honest measure of what is being rebuilt underneath the expiries. A third pressure sits on top of the patent clock and is independent of it: government price-setting now reaches the largest product in the book. | Two real moats and one expensive bet. Launch and Starlink rest on facts the filing states outright: barriers of capital, technology, licences, spectrum and orbital resources; about 9,600 satellites, roughly 75% of all active maneuverable satellites in orbit; the only globally available low-latency network; a NASA-cited cost per kilogram about 85% below the historical average; a first stage reflown 34 times. Connectivity rivals buy launches from it. What caps it: satellites live three to five years and must be perpetually replaced; H1 2026 Falcon launches and mass to orbit both fell and Falcon 9 flights are expected to decline; about 20% of 2025 revenue is U.S. federal, competitively bid and terminable at will; 86% of Q2 capex ($15.8bn of $18.4bn) went to an AI segment whose cloud revenue sits with few customers on 90-day-terminable contracts. Q2 operating loss $143M; H1 loss $2,086M. |
| Chain position | Downstream AI-cloud operator: owns grid-connected data centers and deploys NVIDIA/AMD GPU systems it rents to hyperscalers, frontier labs, AI developers and enterprises (anchor customers Microsoft and NVIDIA). | Demand side of the AI chain, not a supplier into it. The 10-K lists 'Scale AI across our business' as one of four 2026 key priorities and describes 'expanding automation, data-driven decision making, and enterprise AI solutions', crediting 'enhanced digital enablement, including automation and AI' for part of the savings in its cost-realignment and R&D-simplification programs. It describes no AI model, tool or platform that Pfizer sells. | — |
| Products (share / barrier) |
|
|
|
| Long-horizon vote | -0.20 at weight 0.20 · swarm bearish Editorial prior, not backtested. | -0.17 at weight 0.20 · swarm bearish Editorial prior, not backtested. | +0.20 at weight 0.20 · swarm bearish Editorial prior, not backtested. |